Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Function-based mutation-resistant synthetic signaling device activated by HIV-1 proteolysis.

Majerle A, Gaber R, Benčina M, Jerala R.

ACS Synth Biol. 2015 Jun 19;4(6):667-72. doi: 10.1021/sb5002483. Epub 2014 Nov 18.

2.

Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Wapling J, Srivastava S, Shehu-Xhilaga M, Tachedjian G.

Drug Target Insights. 2007;2:159-82. Epub 2007 Jul 20.

3.

Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.

Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A, Cowburn D, Freed EO, Debnath AK.

Retrovirology. 2011 May 3;8:28. doi: 10.1186/1742-4690-8-28.

4.

NMRDyn: a program for NMR relaxation studies of protein association.

Wang CK, Schirra HJ, Craik DJ.

PLoS One. 2008;3(11):e3820. doi: 10.1371/journal.pone.0003820. Epub 2008 Nov 26.

5.

Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Miklóssy G, Tözsér J, Kádas J, Ishima R, Louis JM, Bagossi P.

Protein Eng Des Sel. 2008 Jul;21(7):453-61. doi: 10.1093/protein/gzn022. Epub 2008 May 13.

6.
7.

Herpesvirus protease inhibition by dimer disruption.

Shimba N, Nomura AM, Marnett AB, Craik CS.

J Virol. 2004 Jun;78(12):6657-65.

8.

Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance.

Wang W, Kollman PA.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14937-42.

9.

The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).

Unal A, Pray TR, Lagunoff M, Pennington MW, Ganem D, Craik CS.

J Virol. 1997 Sep;71(9):7030-8.

Items per page

Supplemental Content

Write to the Help Desk